All In Biotech

Drug Trial Radar · NCT00005044

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,579 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,579

Actual

Start

Feb 2000

Primary completion

Sep 2012

Study completion May 20, 2022

Sponsor

Lead sponsor
Radiation Therapy Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • CasodexDrug

    Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.

  • EulexinDrug

    Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.

  • LHRH agonistDrug

    LHRH agonist of choice. The manufacturer's instructions should be followed.

  • radiation therapyRadiation

    \[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-specific Survival (DSS) (10-year Rates Reported)Time frame: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)

Locations

261 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Comprehensive Cancer Center

    Birmingham, Alabama

  • Comprehensive Cancer Institute

    Huntsville, Alabama

  • Huntsville Hospital

    Huntsville, Alabama

  • MBCCOP - Gulf Coast

    Mobile, Alabama

  • Montgomery Cancer Center

    Montgomery, Alabama

  • DCH Cancer Treatment Center

    Tuscaloosa, Alabama

  • Foundation for Cancer Research and Education

    Phoenix, Arizona

  • Providence Saint Joseph Medical Center - Burbank

    Burbank, California

  • Mount Diablo Medical Center

    Concord, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • California Cancer Center

    Fresno, California

  • Saint Agnes Cancer Center

    Fresno, California

  • Sutter Health Western Division Cancer Research Group

    Greenbrae, California

  • Loma Linda University Cancer Institute at Loma Linda University Medical Center

    Loma Linda, California

  • Veterans Affairs Medical Center - Long Beach

    Long Beach, California

  • USC/Norris Comprehensive Cancer Center and Hospital

    Los Angeles, California

  • Jonsson Comprehensive Cancer Center, UCLA

    Los Angeles, California

  • CCOP - Bay Area Tumor Institute

    Oakland, California

  • Huntington Cancer Center at Huntington Hospital

    Pasadena, California

  • Robert and Beverly Lewis Family Cancer Care Center

    Pomona, California

  • Radiation Oncology Center - Sacramento

    Sacramento, California

  • Radiation Medical Group, Incorporated

    San Diego, California

  • Naval Medical Center - San Diego

    San Diego, California

  • UCSF Comprehensive Cancer Center

    San Francisco, California

  • O'Connor Hospital

    San Jose, California

  • CCOP - Santa Rosa Memorial Hospital

    Santa Rosa, California

  • Torrance Memorial Medical Center

    Torrance, California

  • David Grant Medical Center

    Travis Air Force Base, California

  • Memorial Hospital Cancer Center

    Colorado Springs, Colorado

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center

    Denver, Colorado

  • CCOP - Colorado Cancer Research Program, Incorporated

    Denver, Colorado

  • St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

    Grand Junction, Colorado

  • Hospital of St. Raphael

    New Haven, Connecticut

  • Yale Comprehensive Cancer Center

    New Haven, Connecticut

  • CCOP - Christiana Care Health Services

    Newark, Delaware

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • 21st Century Oncology - Fort Myers

    Fort Myers, Florida

  • Shands Cancer Center at the University of Florida Health Science Center

    Gainesville, Florida

  • Florida Radiation Oncology Group

    Jacksonville, Florida

  • Holmes Regional Medical Center

    Melbourne, Florida

Showing 40 of 261 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.